AMCP webinar that provided an overview of the current state of biosimilars in the US, description of some barriers to utilization, discussion of real-world data and how stakeholders may use real-world evidence to inform treatment and coverage decisions, and an update on the efforts of BBCIC.
The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
AMCP webinar that addresses the science behind data consortiums, and also looks at why AMCP is engaging data consortiums, managed care specialty drug experts, researchers and industry to help launch the AMCP Biosimilars Collective Intelligence Consortium before the first biosimilars hit the market.
